| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
|
Arthritis Rheum
|
2012
|
6.85
|
|
2
|
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
|
J Am Soc Nephrol
|
2009
|
5.02
|
|
3
|
Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
|
N Engl J Med
|
2011
|
4.08
|
|
4
|
Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus.
|
Arthritis Rheum
|
2007
|
1.98
|
|
5
|
Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis.
|
Rheumatology (Oxford)
|
2010
|
1.88
|
|
6
|
Defining Clinical Improvement in Adult and Juvenile Myositis.
|
J Rheumatol
|
2003
|
1.75
|
|
7
|
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study.
|
J Rheumatol
|
2009
|
1.67
|
|
8
|
Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years.
|
Rheumatology (Oxford)
|
2009
|
1.50
|
|
9
|
Cancer risk in systemic lupus: an updated international multi-centre cohort study.
|
J Autoimmun
|
2013
|
1.47
|
|
10
|
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
|
Arthritis Care Res (Hoboken)
|
2011
|
1.45
|
|
11
|
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
|
Ann Rheum Dis
|
2014
|
1.45
|
|
12
|
Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al.
|
Arthritis Rheum
|
2006
|
1.39
|
|
13
|
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.
|
Autoimmun Rev
|
2011
|
1.27
|
|
14
|
Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
|
Curr Opin Pharmacol
|
2004
|
1.22
|
|
15
|
The rate and pattern of organ damage in late onset systemic lupus erythematosus.
|
J Rheumatol
|
2002
|
1.10
|
|
16
|
Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.
|
Autoimmun Rev
|
2009
|
1.03
|
|
17
|
B cell depletion in autoimmune disease.
|
Arthritis Res Ther
|
2003
|
1.03
|
|
18
|
Lymphoma risk in systemic lupus: effects of disease activity versus treatment.
|
Ann Rheum Dis
|
2013
|
1.03
|
|
19
|
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome.
|
Ann Rheum Dis
|
2012
|
1.02
|
|
20
|
Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.
|
Rheumatology (Oxford)
|
2010
|
1.02
|
|
21
|
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
|
Arthritis Res Ther
|
2013
|
0.99
|
|
22
|
Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).
|
Arthritis Care Res (Hoboken)
|
2011
|
0.97
|
|
23
|
Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment.
|
Lancet
|
2013
|
0.96
|
|
24
|
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
|
Arthritis Rheum
|
2010
|
0.94
|
|
25
|
The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
|
Arthritis Res Ther
|
2004
|
0.92
|
|
26
|
Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens.
|
J Immunol
|
2006
|
0.92
|
|
27
|
Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions.
|
J Immunol
|
2009
|
0.90
|
|
28
|
Clinical trials in lupus: what have we learned so far?
|
Rheumatology (Oxford)
|
2010
|
0.89
|
|
29
|
Imaging in CNS lupus.
|
Best Pract Res Clin Rheumatol
|
2005
|
0.88
|
|
30
|
The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey.
|
Rheumatology (Oxford)
|
2013
|
0.88
|
|
31
|
Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus.
|
Scand J Rheumatol
|
2002
|
0.86
|
|
32
|
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
|
Rheumatology (Oxford)
|
2010
|
0.83
|
|
33
|
Evaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies.
|
Mol Immunol
|
2011
|
0.83
|
|
34
|
25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.83
|
|
35
|
The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus.
|
J Rheumatol
|
2010
|
0.83
|
|
36
|
Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort.
|
Arthritis Care Res (Hoboken)
|
2015
|
0.82
|
|
37
|
Effect of gender on clinical presentation in systemic lupus erythematosus.
|
Rheumatology (Oxford)
|
2013
|
0.81
|
|
38
|
Decreased live births in women with systemic lupus erythematosus.
|
Arthritis Care Res (Hoboken)
|
2011
|
0.80
|
|
39
|
Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and review of the literature.
|
Clin Exp Rheumatol
|
2010
|
0.80
|
|
40
|
Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus.
|
Rheumatology (Oxford)
|
2013
|
0.79
|
|
41
|
American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort.
|
J Rheumatol
|
2014
|
0.79
|
|
42
|
Treatment of rheumatoid arthritis is good medicine.
|
BMJ
|
2011
|
0.79
|
|
43
|
Mixed connective tissue disease: still crazy after all these years.
|
Rheum Dis Clin North Am
|
2005
|
0.79
|
|
44
|
Assessment of patients with primary Sjögren's syndrome--outcome over 10 years using the Sjögren's Syndrome Damage Index.
|
Rheumatology (Oxford)
|
2010
|
0.78
|
|
45
|
Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies.
|
Best Pract Res Clin Rheumatol
|
2009
|
0.78
|
|
46
|
Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis.
|
Arthritis Rheum
|
2011
|
0.77
|
|
47
|
Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study.
|
Arthritis Res Ther
|
2014
|
0.77
|
|
48
|
Towards treating lupus nephritis without oral steroids: a dream-come-true?
|
Ann Rheum Dis
|
2013
|
0.76
|
|
49
|
Malignancy and rheumatic disease--a real association?
|
J Rheumatol
|
2005
|
0.76
|
|
50
|
Further thoughts about the ILLUMINATE studies of tabalumab in SLE.
|
Ann Rheum Dis
|
2015
|
0.75
|
|
51
|
"Muscles … and bones".
|
Arthritis Rheum
|
2010
|
0.75
|
|
52
|
Working together to improve rheumatology services.
|
Clin Med
|
2006
|
0.75
|
|
53
|
Working through the recession.
|
Rheumatology (Oxford)
|
2010
|
0.75
|
|
54
|
Making sure the treatment of myositis does not get "lost in translation".
|
Curr Opin Rheumatol
|
2004
|
0.75
|
|
55
|
Risk factors for renal disease in systemic lupus erythematosus and their clinical implications.
|
Expert Rev Clin Immunol
|
2015
|
0.75
|
|
56
|
Therapeutic potential (1).
|
Lupus
|
2008
|
0.75
|